JP2025038139A5 - - Google Patents

Download PDF

Info

Publication number
JP2025038139A5
JP2025038139A5 JP2024221508A JP2024221508A JP2025038139A5 JP 2025038139 A5 JP2025038139 A5 JP 2025038139A5 JP 2024221508 A JP2024221508 A JP 2024221508A JP 2024221508 A JP2024221508 A JP 2024221508A JP 2025038139 A5 JP2025038139 A5 JP 2025038139A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
inhibitor
vaccinia virus
granulopoiesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024221508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025038139A (ja
Filing date
Publication date
Priority claimed from PCT/KR2020/011648 external-priority patent/WO2021040496A1/ko
Application filed filed Critical
Publication of JP2025038139A publication Critical patent/JP2025038139A/ja
Publication of JP2025038139A5 publication Critical patent/JP2025038139A5/ja
Pending legal-status Critical Current

Links

JP2024221508A 2019-08-29 2024-12-18 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物 Pending JP2025038139A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20190106736 2019-08-29
KR10-2019-0106736 2019-08-29
PCT/KR2020/011648 WO2021040496A1 (ko) 2019-08-29 2020-08-31 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물
JP2022509096A JP2022545191A (ja) 2019-08-29 2020-08-31 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022509096A Division JP2022545191A (ja) 2019-08-29 2020-08-31 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Publications (2)

Publication Number Publication Date
JP2025038139A JP2025038139A (ja) 2025-03-18
JP2025038139A5 true JP2025038139A5 (https=) 2025-05-28

Family

ID=74685712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509096A Pending JP2022545191A (ja) 2019-08-29 2020-08-31 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物
JP2024221508A Pending JP2025038139A (ja) 2019-08-29 2024-12-18 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022509096A Pending JP2022545191A (ja) 2019-08-29 2020-08-31 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Country Status (8)

Country Link
US (1) US20220288143A1 (https=)
EP (1) EP4023235A4 (https=)
JP (2) JP2022545191A (https=)
KR (1) KR102661908B1 (https=)
CN (1) CN114630683A (https=)
AU (1) AU2020337054B9 (https=)
CA (1) CA3152973A1 (https=)
WO (1) WO2021040496A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7704419B2 (ja) * 2019-06-27 2025-07-08 バイオノックス インコーポレイテッド 安全性及び抗がん効果が改善された腫瘍溶解性ウイルス
KR102739298B1 (ko) * 2021-04-02 2024-12-06 주식회사 바이오녹스 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편
CN118443941A (zh) * 2024-04-29 2024-08-06 山东大学齐鲁医院 中性粒细胞作为诊疗膀胱癌的靶标的应用
CN119955859A (zh) * 2025-01-24 2025-05-09 郑州大学 F14l基因缺失和表达腺苷脱氨酶的溶瘤痘苗病毒载体的构建方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
EP2073823A1 (en) * 2006-10-13 2009-07-01 Medigene AG Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
CA2709292A1 (en) * 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders
WO2013112942A1 (en) * 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
KR101632897B1 (ko) * 2013-04-10 2016-06-23 신라젠(주) 백시니아 바이러스로부터 유래한 신규한 항암 바이러스 ｈｂｂ３０１
WO2017205674A1 (en) * 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
AU2017332367B2 (en) * 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
US11857585B2 (en) * 2017-12-28 2024-01-02 Bionoxx Inc. Oncolytic virus improved in safety and anticancer effect
CN112584852A (zh) * 2018-06-19 2021-03-30 百欧恩泰美国公司 新抗原及其用途
CA3150829A1 (en) * 2019-08-26 2021-03-04 Bionoxx Inc. Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer
CN114364390A (zh) * 2019-08-26 2022-04-15 拜耳诺克斯有限公司 用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物

Similar Documents

Publication Publication Date Title
JP2025038139A5 (https=)
KR101542275B1 (ko) 폭스바이러스성 온콜리틱 벡터
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
US9884080B2 (en) Poxviral oncolytic vectors
US11452770B2 (en) Recombinant vaccinia virus and use thereof
CN108841796A (zh) 重组单纯疱疹病毒及其制备方法和应用
WO2019080537A1 (zh) 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
KR102381952B1 (ko) 항암바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
JP2023552289A5 (https=)
KR102789416B1 (ko) 항암 바이러스 및 이의 용도
CA2943871C (en) POXVIRAL ONCOLYTIC VECTORS
JP2017515806A5 (https=)
CN111939262A (zh) 一种治疗肿瘤或癌症的药物组合物和其应用
EP4206327A1 (en) Mutant ovis spp. infectious pustular dermatitis virus and use thereof
HK1262966A1 (en) Recombinant herpes simplex virus as well as preparation method and application thereof
HK1230971B (en) Poxviral oncolytic vectors
HK1230971A1 (en) Poxviral oncolytic vectors
HK1141314B (en) Poxviral oncolytic vectors
HK1141541B (en) Poxviral oncolytic vectors